News

GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences

CARLSBAD, Calif., /PRNewswire/ — GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company’s advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the system‘s upcoming commercial introduction. Anticipating the commercial launch, the company is changing its name to “Curate Biosciences” to better communicate its benefits to the gene and cell therapy industry

Cell therapies, typically made from a patient’s own cells, are increasingly important in the fight against cancer and other critical diseases. Curate Biosciences provides a superior cell separation, wash, and concentration solution to deliver more biologically potent results for revolutionary cell therapy treatments. 

The company’s Curate® Cell Processing System is a robust, simple, and automated system that has the potential to enable up to a 50% reduction in the total cost of autologous cell therapy production and a like reduction in the days required to produce a CAR-T dose. The Curate System more than doubles the recovery of patient-derived white blood cells and CD3+ T cell subsets, with exceptional purity in a single-step, closed microfluidic system. 

“Users are now testing the Curate System via our Technology Access Program and observing firsthand its innovative and industry leading ability to produce more high-quality white blood cells for CAR-T oncology cures,” said Mike Grisham, Curate Bioscience’s Chief Executive Officer. “GPB in our prior company name stood for getting people better,’ and this remains our core mission, but the new name reflects our unique capacity to provide more high-quality cells to produce cures for once-intractable diseases.

For more information visit https://www.curatebio.com/

Recent News

09/09/2025

ATCC Receives Contract to Advance Industrial Biomanufacturing and Produce Synthetic Aviation Fuel Precursors

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been granted a contract with Capra Biosciences, a Virginia-based biotech company focused on the cost-competitive production of petrochemical replacements using its modular bioreactor platform. ATCC is supporting a contract with Capra to work on the Defense Advanced Research Projects Agency’s

09/05/2025

RIVANNA awarded $2.21 million NIH grant to develop pediatric lumbar puncture ultrasound guidance system

RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) Direct to Phase II (R44) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop an ultrasound guidance solution for pediatric lumbar punctures (LPs) on its Accuro® 3S platform. Lumbar punctures

09/03/2025

Cupron Performance Additives (“Cupron”) announces new distribution relationship with Palmer Holland

Cupron Performance Additives (Cupron) announced today the launch of an exclusive distribution agreement with Palmer Holland, leading North American distributor of specialty additives for the engineered materials marketplace. Palmer Holland will distribute Cupron’s copper-based antimicrobial and anti-odor technologies into plastics, films, foams, and polymeric systems throughout North America. The Cupron line effectively complements Palmer Holland’s